InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,439.89
(
0.30%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

BioSpecialist

Send PM Follow Ignore
Followers 129
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

BioSpecialist

Re: BioSpecialist post# 74343

Tuesday, 03/17/2009 10:21:06 PM

Tuesday, March 17, 2009 10:21:06 PM

Post# of 252302
re synthetic heparin << ANDA filing

on the move ....
http://finance.yahoo.com/q/bc?s=ACL.AX&t=5d&l=on&z=m&q=l&c=


17-Mar-2009
Investor Presentation
http://www.alchemia.com.au/IRM/Company/ShowPage.aspx?CPID=1387&PageName=Investor%20Presentation

Summary
􀁨 ANDA submitted to US FDA for fondaparinux
􀁨 Launch anticipated in H2 2009
􀁨 Significant revenue opportunity
􀁨 Preparing for pivotal Phase III trial of HA-irinotecan
􀁨 Opportunity to commence metastatic colorectal cancer trial in 2009
􀁨 Multiple opportunities for HyACT technology
􀁨 Supergenerics
􀁨 Lifecycle management
􀁨 Antibodies
􀁨 24months cash, sufficient to reach fondaparinux revenues
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up